2025-05-01 - Analysis Report
## Recursion Pharmaceuticals Inc (RXRX) Stock Analysis

This report analyzes Recursion Pharmaceuticals Inc (RXRX), a clinical-stage biopharmaceutical company applying AI to drug discovery.

**1) Performance Comparison & Divergence:**

RXRX's cumulative return of -48.87% significantly underperforms the S&P 500 (VOO) with a cumulative return of 17.83%.  The current divergence is -66.7%, placing it at the 6.3rd percentile of its historical range (max: 26.6%, min: -73.0%).  This indicates RXRX has considerably underperformed the market historically, and currently sits near the lower bound of its historical underperformance relative to the S&P 500.


**Alpha & Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 5.0% | 73.6% | -12.0% | 4.0 |
| 2022-2024  | 0.0% | 73.6% | -22.0% | 2.8 |
| 2023-2025  | 3.0% | 73.6% | -14.0% | 2.3 |

The analysis shows consistently negative alpha values, suggesting underperformance relative to the market.  The high beta values (significantly above 1) indicate high volatility and a strong correlation with overall market movements.  The market capitalization has also shrunk considerably during the analyzed period.

**2) Recent Price Movement:**

* **Closing Price:** $5.59
* **Previous Close:** $5.72
* **Change:** -2.27% (a small price drop)
* **5-day Moving Average:** $5.73
* **20-day Moving Average:** $5.23
* **60-day Moving Average:** $6.62

The price is currently below all three moving averages, suggesting a potential downward trend.  The recent price drop is relatively modest.


**3) Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.37 (Medium Risk)
* **RSI:** 64.78 (Slightly above neutral; not overbought)
* **PPO:** 2.15 (Positive, suggesting potential upward momentum)
* **20-day Relative Divergence Change:** -3.9% (Short-term downward trend)
* **Expected Return:** -545.9% (This extremely negative value requires further investigation and likely reflects an error or extreme pessimism.  It's crucial to examine the methodology used to arrive at this figure).  The expected return is exceptionally negative compared to the S&P 500, suggesting very poor outperformance even with long-term, buy-and-hold strategy.


**4) Recent Earnings Analysis:**

| Date       | EPS     | Revenue    |
|------------|---------|------------|
| 2024-11-06 | -$0.34  | $0.03 B    |
| 2024-08-08 | -$0.40  | $0.01 B    |
| 2024-05-09 | -$0.39  | $0.01 B    |
| 2023-11-09 | -$0.43  | $0.01 B    |
| 2024-11-06 | -$0.43  | $0.01 B    | *(Duplicate entry, likely an error)*


The company is consistently reporting negative EPS, indicating losses. Revenue is low and relatively stagnant.  The duplicate entry should be investigated and corrected.


**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $0.00B | -183.62% |
| 2024-09-30 | $0.03B | 53.69% |
| 2024-06-30 | $0.01B | 36.14% |
| 2024-03-31 | $0.01B | 17.23% |
| 2023-12-31 | $0.01B | 6.99% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $1.03B | -17.29% |
| 2024-09-30 | $0.52B | -18.27% |
| 2024-06-30 | $0.58B | -16.69% |
| 2024-03-31 | $0.40B | -22.78% |
| 2023-12-31 | $0.46B | -20.07% |

The financial data reveals significant inconsistencies and potential errors (e.g., -183.62% profit margin).  The negative profit margins and ROE consistently demonstrate substantial losses and poor profitability.  This warrants a thorough review of the financial statements.


**6) Overall Analysis:**

Recursion Pharmaceuticals (RXRX) shows significant underperformance against the S&P 500, marked by consistently negative alpha, high beta, and substantial losses.  The financial data requires careful scrutiny due to inconsistencies. While the RSI and PPO suggest some potential for upward momentum, the overall picture is overwhelmingly negative.  The extremely negative expected return (-545.9%) needs clarification and validation.  Investors should exercise extreme caution, conduct thorough due diligence, and carefully consider the significant risks associated with this investment.  The provided data indicates considerable financial distress and underperformance.  Further investigation is crucial before any investment decision is made.
